Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2005 2
2006 4
2007 4
2008 4
2009 9
2010 6
2011 8
2012 10
2013 6
2014 6
2015 8
2016 5
2017 5
2018 3
2019 6
2020 6
2021 5
2022 7
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Results by year

Filters applied: . Clear all
Page 1
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Feagan BG, et al. N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734. N Engl J Med. 2013. PMID: 23964932 Free article. Clinical Trial.
Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Sandborn WJ, et al. N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739. N Engl J Med. 2013. PMID: 23964933 Free article. Clinical Trial.
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK; NOR-SWITCH study group. Jørgensen KK, et al. Lancet. 2017 Jun 10;389(10086):2304-2316. doi: 10.1016/S0140-6736(17)30068-5. Epub 2017 May 11. Lancet. 2017. PMID: 28502609 Clinical Trial.
Cellular and Molecular Mediators of Intestinal Fibrosis.
Lawrance IC, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G, Reif S, Speca S, Latella G. Lawrance IC, et al. Among authors: florholmen j. J Crohns Colitis. 2017 Dec 4;11(12):1491-1503. doi: 10.1016/j.crohns.2014.09.008. J Crohns Colitis. 2017. PMID: 25306501 Free PMC article. Review.
The role of interleukin-17A in colorectal tumorigenesis.
Shi Y, Lin H, Cui J, Qi H, Florholmen J, Liu Z, Cui G. Shi Y, et al. Among authors: florholmen j. Cancer Biother Radiopharm. 2013 Jul-Aug;28(6):429-32. doi: 10.1089/cbr.2012.1396. Epub 2013 May 23. Cancer Biother Radiopharm. 2013. PMID: 23701420 Review.
Transcriptomic Landscape of Treatment-Naïve Ulcerative Colitis.
Taman H, Fenton CG, Hensel IV, Anderssen E, Florholmen J, Paulssen RH. Taman H, et al. Among authors: florholmen j. J Crohns Colitis. 2018 Feb 28;12(3):327-336. doi: 10.1093/ecco-jcc/jjx139. J Crohns Colitis. 2018. PMID: 29040430 Free PMC article.
100 results